health
Otsuka Establishes Ulefnersen Early Access Program (EAP) for Eligible People Living with FUS-ALS
PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. today announced the initiation of a global early access program (EAP) for ulefnersen, an investigational RNA-targeted medicine, for eligible people living with a genetic subtype of amyotrophic lateral sclerosis (ALS) known as FUS-ALS, caused by mutations in the fused in sarcoma (FUS) gene1, who have a confirmed genetic diagnosis and meet predefined program eligibility criteria. FUS-ALS is a rare fo
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
Businesswire
QT Imaging to be Honored at Premier’s Annual Supplier Innovation Celebration
Businesswire
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
Businesswire
China takes decisive action to advance global development
Pr Newswire Apac
Project RED Expands Oregon's Overdose Prevention Efforts with Support from Boulder Care and Pearl Jam’s Vitalogy Foundation
Businesswire